Onconetix (NASDAQ:ONCO) Major Shareholder Financial Lp Hrt Sells 94,462 Shares of Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt sold 94,462 shares of the business’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $0.75, for a total value of $70,846.50. Following the transaction, the insider owned 83,359 shares of the company’s stock, valued at approximately $62,519.25. The trade was a 53.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The shares were sold at an average price of $0.73, for a total value of $39,322.91.
• On Friday, April 17th, Financial Lp Hrt acquired 34,636 shares of Onconetix stock. The shares were acquired at an average price of $0.73 per share, with a total value of $25,284.28.
• On Wednesday, April 15th, Financial Lp Hrt acquired 92,554 shares of Onconetix stock. The shares were acquired at an average price of $0.76 per share, with a total value of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt bought 74,350 shares of Onconetix stock. The shares were purchased at an average cost of $0.77 per share, with a total value of $57,249.50.

Onconetix Stock Down 7.5%

Shares of NASDAQ ONCO opened at $0.68 on Wednesday. The business has a fifty day simple moving average of $2.62 and a two-hundred day simple moving average of $8.51. The firm has a market cap of $446,688.00, a PE ratio of 0.00 and a beta of 3.63. Onconetix, Inc. has a twelve month low of $0.66 and a twelve month high of $74.29.

Institutional Investors Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Citadel Advisors LLC bought a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned approximately 1.00% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by hedge funds and other institutional investors.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.